Less chemoradiation is possible for some cancer patients

Scaling back treatment can mean better quality of life for oropharynx cancer patients who qualify

5:00 AM

Author | Tessa Roy

cancer cell blue yellow
Credit: Justine Ross, Jacob Dwyer, Michigan Medicine

Some oropharynx cancer patients may qualify for less radiation treatments, according to a new study from experts at the University of Michigan Health Rogel Cancer Center. This could assist many patients in a quicker return to their normal lives. 

Oropharynx cancer was historically related to smoking and alcohol use, but now most cases diagnosed in the United States are caused by the human papillomavirus (HPV). HPV+ oropharynx cancer is recognized as being biologically different from HPV negative cancer, with a better prognosis. 

A standard treatment for oropharynx cancer involves seven weeks of daily radiation – a total of 35 treatments given over the course of five days per week – given with chemotherapy, which causes of side effects like pain, difficulty swallowing, dry mouth, and loss of taste. 

However, most patients with HPV+ oropharynx cancer can be cured with chemoradiation and tend to be younger and healthier compared to those with HPV negative oropharynx cancer. According to the study? That means those patients both may not need the standard amount of treatment and risk being left with the long term toxicities from treatment. 

“Since most patients with HPV+ oropharynx cancer respond very well to treatment and will be cured, there is significant interest in minimizing the amount of treatment they receive to decrease short term side effects and reduce the risk of long term complications,” said Samuel Regan, M.D., a radiation oncology physician at U-M Health. 

“In this study, we hypothesized that patients who have an early response to treatment have more favorable disease that is responsive to radiation, and they could therefore stop early and receive less chemoradiation. Patients who didn't respond quickly still got the standard treatment to ensure we don't compromise the chance of curing their cancer,” adds Michelle Mierzwa, M.D. the primary investigator of the study and associate professor of radiation oncology at U-M Health.   

Experts found that patients who received de-escalated treatment had significantly less weight loss after treatment, tended to need a feeding tube less often, and experienced less worsening of symptoms or less severe symptoms. The study demonstrated that de-escalated chemoradiation is feasible for some patients, and that recurrence rates for patients treated on the trial are similar to those already recorded at Michigan Medicine.   

Though additional research on treatment will be needed, Regan says de-escalated treatments, can make a meaningful difference on a patient’s quality of life. Mierzwa adds that further studies are needed to verify longer term outcomes in these patients.   

"Safely decreasing the amount of chemoradiation needed means that patients could tolerate treatment better and may return back to their normal lives sooner, while keeping the risk of cancer returning low,” Regan said.  

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week by subscribing to Health Lab’s two newsletters, Health & Wellness and Research & Innovation.

Sign up for the Health Lab Podcast: Add us on SpotifyApple Podcasts or wherever you get you listen to your favorite shows.


More Articles About: Cancer: Cancer Types Cancer: Help, Diagnosis & Treatment Cancer Diagnosis Cancer Risk Factors Chemotherapy Radiation Oncology
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Related
doctor in white coat scanning person in machine with words "lab note" written on yellow badge with blue font bottom right
Health Lab
Statewide quality improvement project reduced excessive radiation treatments for bone metastases by 80%
The effort by the Michigan Radiation Oncology Quality Consortium reduced unnecessary medical procedures, and saved the time and resources of patients and families.
Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Blue image of a microscopic helix strand
Health Lab
Researchers discover urine based test to detect head and neck cancer
At-home test can detect tumor DNA fragments in urine samples, providing a non-invasive alternative to traditional blood-based biomarker tests
Health Lab
Father’s cancerous brain tumor found weeks after the birth of his daughter
Father’s cancerous brain tumor found weeks after the birth of his daughter
Speculum illustration including a gloved hand holding a swab in front of microscopic cells
Health Lab
U.S. could cut cervical cancer cases, deaths by up to 20% if more patients followed up after screening, study suggests
Many women don’t get cervical cancer screening such as Pap tests, or don’t go for follow up diagnostic tests; a new study shows what could happen if all of them did.
Spilled pills next to a stethoscope and pile of cash
Health Lab
Drug pricing program improved prostate cancer treatment adherence
Socially vulnerable patients were more likely to stick with oral medications when treated at a hospital participating in 340B program, suggesting these hospitals may have more resources to help patients.
Microscopic image of bone marrow with pink and white hues
Health Lab
Novel risk score for cardiovascular complications after bone marrow transplant
More bone marrow transplants, also known as hematopoietic stem cell transplantation, are being offered to older patients, a population at greater risk of cardiovascular disease.
Animated microscopic image of the glioblastoma's tumor microenvironment
Health Lab
New model of key brain tumor feature could help scientists understand how to develop new treatments
Model shows how oncostreams form and behave in brain tumors – and how to inhibit them